Specialised Therapeutics
Specialised Therapeutics is an independent specialty pharmaceutical company that commercialises novel third-party therapies under exclusive distribution agreements across Australia, New Zealand, and Southeast Asia, serving patients with rare cancers, haematological conditions, endocrinology, and ophthalmology needs via PBS and field sales.
- Company typePrivate
- Founded2007
- HeadquartersSingapore, Singapore
- Headcount11–50
- GTM typeB2B
- OfferingHardware or Manufacturing
What Specialised Therapeutics does
Specialised Therapeutics (ST) is an independent specialty pharmaceutical company founded in 2007 and headquartered in Singapore. The company commercialises novel therapies under exclusive distribution and licensing agreements with international pharmaceutical developers, serving patients in Australia, New Zealand, Singapore, Malaysia, Brunei, Thailand, Vietnam, and the Philippines. Its core activity is not drug discovery but rather the regulatory navigation (Australia's TGA via Priority Review and Project Orbis; Singapore's HSA), reimbursement listing (Australia's PBS, named-patient and Special Access Schemes), field sales, medical affairs, and supply chain operations required to bring approved specialty medicines to market across the region.
ST's product portfolio spans oncology (ZEPZELCA/lurbinectedin, NERLYNX/neratinib, ABRAXANE/nab-paclitaxel, ICLUSIG/ponatinib, PEMAZYRE/pemigatinib, Zynyz/retifanlimab), haematology (MINJUVI/tafasitamab, NIKTIMVO/axatilimab), endocrinology (YORVIPATH/palopegteriparatide, SKYTROFA/lonapegsomatropin using Ascendis Pharma's TransCon prodrug platform), ophthalmology (ILUVIEN/fluocinolone acetonide), and supportive care (AKYNZEO, GELCLAIR). The technologies commercialised are exclusively third-party—ranging from monoclonal antibodies (CD19-targeted tafasitamab, CSF-1R-blocking axatilimab) to kinase inhibitors and prodrug sustained-release platforms—with ST holding no proprietary R&D pipeline of its own.
The business model is distribution-and-licensing: ST signs exclusive territorial agreements with drug developers (18 disclosed partners including Incyte, Ascendis Pharma, Puma Biotechnology, Helsinn, PharmaMar, Alimera Sciences, ARIAD, Bristol-Myers Squibb, Deciphera, and Akeso), assumes responsibility for local regulatory approvals and PBS/HSA submissions, deploys field sales representatives and oncology/haematology medical liaisons to engage healthcare professionals and hospitals, and earns revenue through product sales. Pricing is administered via government reimbursement schemes, with most products listed or pursuing PBS listings. The company is privately held with no disclosed external investors, no parent company, and no disclosed revenue, headcount, or funding figures; CEO Carlo Montagner has led the company in its independent posture since founding.
Specialised Therapeutics firmographics
Firmographics- Name
- Specialised Therapeutics
- Legal name
- Specialised Therapeutics
- Website
- https://stabiopharma.com
- Company type
- Private
- Founded year
- 2007
- Operating status
- Operating
- Headcount range
- 11–50 employees
- Short description
- Specialised Therapeutics is an independent specialty pharmaceutical company that commercialises novel third-party therapies under exclusive distribution agreements across Australia, New Zealand, and Southeast Asia, serving patients with rare cancers, haematological conditions, endocrinology, and ophthalmology needs via PBS and field sales.
- Ownership category
- akta.pro rank
Specialised Therapeutics industry classification
Industry- Product category
- Specialty Pharmaceuticals
- NAICS
- Pharmaceutical Preparation Manufacturing (325412), Pharmaceutical and Medicine Manufacturing (3254)
- SIC
- Pharmaceutical Preparations (2834), Wholesale-Drugs, Proprietaries & Druggists' Sundries (5122)
- akta.pro primary industry
- Specialty Injectable & Infusion Therapies (Cross-therapeutic) (HLAIACAO)
- akta.pro secondary industries
- Oncology Specialty Pharmaceuticals (HLAIACAA), Hematology Specialty Pharmaceuticals (Non-malignant) (HLAIACAI), Immunology & Autoimmune Specialty Pharmaceuticals (HLAIACAB)
Keywords
Where Specialised Therapeutics is headquartered
LocationHeadquarters
- HQ city
- Singapore
- HQ country
- Singapore
- HQ region
- Asia
Offices3 records
Markets served
Specialised Therapeutics business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Personnel, Supply Chain, Marketing or Sales, Operations, Technology or R&D
Revenue model
- Pharmaceutical Distribution and Commercialisation: Specialised Therapeutics generates revenue by commercialising specialty pharmaceutical products under exclusive distribution agreements with international pharmaceutical companies. The company obtains regulatory approvals (TGA, HSA) and negotiates reimbursement listings (PBS) to distribute therapies in Australia, New Zealand, Singapore, and Southeast Asia.
Go-to-market motion2 records
Distribution channels4 records
Marketing channels4 records
Specialised Therapeutics product offering
Product offeringCore offering
Specialised Therapeutics is an independent specialty biopharmaceutical company that in-licenses and commercialises specialty pharmaceutical products for the Australia, New Zealand, and Southeast Asia region through exclusive distribution agreements with 18 international pharmaceutical companies. Its portfolio addresses rare cancers, rare diseases, oncology, hematology, and endocrinology, and includes both innovative therapeutics and supportive care products.
Product overview
Specialised Therapeutics is a specialty pharmaceutical company that commercialises a broad portfolio of novel therapies across multiple therapeutic areas including oncology, haematology, CNS, neurology, endocrinology, ophthalmology, and supportive care. The company operates through exclusive partnering agreements with international pharmaceutical companies (primarily Incyte, Ascendis Pharma, Puma Biotechnology, Helsinn, and others) to register and commercialise specialty medicines in Australia, New Zealand, and Southeast Asia. The product portfolio includes targeted cancer therapies (ZEPZELCA, NERLYNX, ABRAXANE, ICLUSIG, PEMAZYRE), haematology treatments (MINJUVI, NIKTIMVO), endocrine therapies (YORVIPATH, SKYTROFA), supportive care products (AKYNZEO, GELCLAIR), and ophthalmology treatments (ILUVIEN). The company focuses on bringing innovative medicines to patients with unmet medical needs through regulatory navigation, reimbursement, and commercialisation in the Asia-Pacific region.
Differentiator
Problem solved
Functional benefit
Brands
- ST: Common abbreviation used for Specialised Therapeutics in press releases and company communications.
Products and services
- NIKTIMVO
Quantifiable outcome
- 74% overall response rate in AGAVE-201 trial for NIKTIMVO in chronic GVHD
- +2 more outcomes
Companies that use Specialised Therapeutics
Customer profileNamed customers1 record
Segments2 records
Ideal customer profiles1 record
Specialised Therapeutics technology and API
TechnologyTechnology focussed No
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Specialised Therapeutics partnerships and signals
Strategic signalPartnerships
14 partnerships are on record, tiered core and secondary.
- Puma BiotechnologycoreST makes NERLYNX (neratinib) available in Thailand under exclusive license from Puma Biotechnology, Inc. (Nasdaq: PBYI).
- IncytecoreIn June 2025, ST expanded its existing partnership with Incyte to include axatilimab (Niktimvo) and retifanlimab (Zynyz), in addition to existing products Minjuvi (tafasitamab) and Pemazyre (pemigatinib). The agreement covers Australia, New Zealand and Singapore with an option to add further countries in Asia-Pacific. Incyte is responsible for development, manufacture and supply while ST handles regulatory, distribution and local marketing activities.
- Ascendis PharmacoreST holds an exclusive distribution agreement with Ascendis Pharma A/S covering Australia, New Zealand, Singapore, Malaysia, Brunei, Thailand, and Vietnam for YORVIPATH (palopegteriparatide) and SKYTROFA (lonapegsomatropin).
- IncytecoreST entered into an exclusive distribution agreement with Incyte in 2021 to commercialise Minjuvi (tafasitamab) in Australia, New Zealand and Singapore.
- HelsinnsecondaryST partnered with Helsinn Group to commercialise AKYNZEO (netupitant/palonosetron) in Australia for the prevention of chemotherapy-induced nausea and vomiting.
- PharmamarsecondaryPartnership to commercialise Zepzelca (lurbinectedin) for small cell lung cancer.
- Puma BiotechnologysecondaryPartnership for NERLYNX (neratinib) for HER2+ breast cancer.
- Alimera SciencessecondaryPartnership to distribute ILUVIEN (fluocinolone acetonide) for diabetic macular oedema in Australia and New Zealand.
- ARIAD PharmaceuticalssecondaryPartnership to commercialise ICLUSIG (ponatinib) for chronic myeloid leukaemia in Australia.
- OnconovasecondaryPartnership for oncology therapies.
- Bristol-Myers SquibbsecondaryPartnership for oncology products.
- Canaria BiosecondaryPartnership for ovarian cancer therapy.
- TreewaysecondaryPartnership for rare disease therapies.
- AkesosecondaryPartnership for biopharmaceutical products.
Scale indicators7 records
Recent moves7 records
Expansion highlights5 records
Specialised Therapeutics competitors and assessment
Company assessmentDirect peers
- Mundipharma: Singapore-headquartered, family-owned independent specialty pharma with a network model across Asia-Pacific and other regions; closely mirrors ST's structure of commercialising partnered assets rather than developing proprietary R&D.
- Zuellig Pharma: Asia-Pacific pharmaceutical distribution and commercialisation specialist partnering with global manufacturers to bring specialty therapies to SE Asia — directly comparable distribution-led, multi-country model.
- DKSH Holding (Healthcare): Swiss-listed market-expansion services group that provides regulatory, distribution and commercialisation for pharma clients across Asia-Pacific; ST operates a similar specialist vertical on a more focused therapeutic base.
- Clinigen Group: UK-listed specialty pharma access and distribution platform providing unlicensed and licensed medicines globally; comparable asset-light, partnership-driven model targeting rare/specialty therapies.
- Norgine: European specialty pharma focused on gastroenterology, oncology supportive care and rare diseases with established Asia-Pacific commercialisation partnerships; comparable specialty-pharma positioning and in-licensed-portfolio model.
Broad incumbents
- Aspen Pharmacare: South African specialty/generics pharma with a substantial ANZ and emerging-market footprint via portfolio of in-licensed and acquired assets; comparable regional commercial-platform play but at far larger scale.
- Hikma Pharmaceuticals: MENA-headquartered specialty/generics pharma with global in-licensing and branded distribution across multiple regions; broad incumbent operating a similar partner-led commercial model.
- Menarini Group (Asia-Pacific): Privately-held Italian pharma group with a growing Asia-Pacific presence distributing in-licensed specialty products; relevant peer for the in-licensed/regional-distribution model though at larger scale.
- Servier (Asia-Pacific): Independent French specialty pharma with an active oncology and rare-disease portfolio distributed through regional partners across APAC; comparable therapeutic focus though operates its own sales infrastructure in some markets.
Emerging players
- Sojournix Pharmaceuticals: An emerging US-listed specialty pharma focused on oncology and rare endocrinology with Asia-Pacific ambitions via partners; representative emerging peer that, like ST, relies on partner-driven specialty launches in niche indications.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat4 records
Key risks7 records
Key highlights7 records
Customer concentration
Specialised Therapeutics social profiles
Digital presenceSpecialised Therapeutics financial estimates
Financial estimateRevenue estimate
Valuation estimate
Specialised Therapeutics leadership team
Management profileNumber of profiles
Profiles1 record
Specialised Therapeutics funding detail
Funding detailFunding overview
Funding rounds
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Specialised Therapeutics M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Specialised Therapeutics
What does Specialised Therapeutics do?
Specialised Therapeutics is an independent specialty biopharmaceutical company that in-licenses and commercialises specialty pharmaceutical products for the Australia, New Zealand, and Southeast Asia region through exclusive distribution agreements with 18 international pharmaceutical companies. Its portfolio addresses rare cancers, rare diseases, oncology, hematology, and endocrinology, and includes both innovative therapeutics and supportive care products.
Is Specialised Therapeutics a public or private company?
Specialised Therapeutics is a private company. It is classified as unknown and is currently operating.
When was Specialised Therapeutics founded?
Specialised Therapeutics was founded in 2007. It employs 11 to 50 people.
Where is Specialised Therapeutics based?
Specialised Therapeutics is headquartered in Singapore, Singapore, in the Asia region.
How does Specialised Therapeutics make money?
One revenue line is on record: pharmaceutical Distribution and Commercialisation.
Who are Specialised Therapeutics's main competitors?
Direct peers on record are Mundipharma, Zuellig Pharma, DKSH Holding (Healthcare), Clinigen Group and Norgine. Broad incumbents are Aspen Pharmacare, Hikma Pharmaceuticals, Menarini Group (Asia-Pacific) and Servier (Asia-Pacific). Sojournix Pharmaceuticals is listed as an emerging player.
Does Specialised Therapeutics have an API?
No public API is recorded for Specialised Therapeutics.
What industry is Specialised Therapeutics in?
Specialised Therapeutics's product category is Specialty Pharmaceuticals. Its primary akta.pro industry code is HLAIACAO, Specialty Injectable & Infusion Therapies (Cross-therapeutic), with a secondary code of HLAIACAA, Oncology Specialty Pharmaceuticals. Its NAICS code is 325412 and its SIC code is 2834.